Cereno Scientific – executive interview

Cereno Scientific (STO: CRNO-B) is a clinical-stage biotech focused on developing innovative treatments for rare indications in the cardiovascular and pulmonary spaces. Its pipeline is led by CS1 and CS014, HDAC inhibitors with disease-modifying potential in pulmonary arterial hypertension and idiopathic pulmonary fibrosis, respectively. Both candidates are backed by promising clinical data and are gearing up for more advanced-stage clinical studies (Phase IIb for CS1 and Phase II for CS014) in H126. A third asset, CS585, a prostacyclin receptor agonist, is currently under preclinical evaluation for cardiovascular indications.

In this interview, we speak with Sten Sörensen, CEO of Cereno Scientific, to discuss developments in the company’s asset pipeline, including the recent FDA fast track designation for CS1 and the positive Phase I results for CS014. Mr Sörensen also provides further insight into the ongoing preparatory work for the upcoming Phase IIb trial for CS1 in H126,as well as the plans for CS014. We cover CS585’s progress as it is expected to enter the clinic in 2027. He also shares his thoughts on the company’s strategic approach to financing the upcoming studies, and potential partnering discussions.